|
|
Article: Genentech, Xenova In Potential $63M Deal For OX40 Program.
- Article from:
- BIOWORLD Today
- Article date:
- November 4, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
BioWorld International Correspondent
Xenova Group plc signed a deal worth up to $63 million that gives Genentech Inc. rights to XenovaEs preclinical OX40 program to develop drugs targeting disorders of the immune system.
Genentech will pay license fees of up to $5 million during the first year of the collaboration, and Xenova could see up to $58 million in milestones based on the clinical development and commercialization of one product, plus royalties on any sales. South San Francisco-based Genentech has an option to develop a second product and would pay milestones and royalties on that product as well.
Xenova CEO David Oxlade said, oThis deal ...
Related newspaper, magazine, and journal articles:
|
|
Article: COMPANY FORGING AHEAD WITH DIABETES DRUG AMYLIN STOCK DROPS 77 ...
BIOWORLD Today;
October 22, 1998 ;
700+ words
... ... price dropped below $8.50. (See BioWorld Today, Aug. 19, 1997, p. 1.) Along ... U.S. and Europe," Krawiec told BioWorld Today. Tanner said Amylin's move to continue ... J $36 million from a loan. (See BioWorld Today, March 3, 1998, p. 1.) Terms ...
|
|